Arvinas ARVN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific external expense by Product | ||||||
| ARV-102 | $20M+9.9% | $21M+61.5% | $20.8M+158% | $20.3M+389% | $18.2M+502% | |
| ARV-393 | $12.2M+48.8% | $11.1M+63.2% | $9.9M+100% | $9M+150% | $8.2M+264% | |
| ARV-806 | $19.1M+516% | $13.5M+487% | $8.9M+709% | $4.6M+1,433% | $3.1M+3,000% | |
| Bavdegalutamide (ARV-110) | $1.8M-77.5% | $2.7M-68.2% | $4M-70.3% | $6.4M-63.2% | $8M-62.9% | |
| Other programs | $5.4M+218% | $4.5M+4,400% | $2.8M+2,700% | $2.5M+2,400% | $1.7M+1,600% | |
| Vepdegestrant ARV-471 | $47.5M-42.0% | $62.7M-18.5% | $66.5M-26.1% | $71.9M-25.6% | $81.9M-16.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arvinas break its business down?
- Arvinas (ARVN) reports program-specific external expense by product across 6 parts — ARV-102, ARV-393, ARV-806, Bavdegalutamide (ARV-110) and Other programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Arvinas's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arvinas's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
